Laguna signs exclusive Canadian Distribution Agreement with Isodiol, a leading CBD supplier and product formulator

Biotech Investing
Biotech Investing

Laguna Blends (CSE:LAG; OTCMKTS:LAGBF; FRA:LB6A) announces that it has signed an exclusive distribution agreement with Iso International, LLC. (“Isodiol). Isodiol is one of the world’s leading suppliers, formulators and manufacturers of pharmaceutical grade CBD products. Isodiol will provide its experience in research, development and manufacturing and offer all of its current products to Laguna on an exclusive basis for the Canadian market.

Laguna Blends (CSE:LAG; OTCMKTS:LAGBF; FRA:LB6A) announces that it has signed an exclusive distribution agreement with Iso International, LLC. (“Isodiol). Isodiol is one of the world’s leading suppliers, formulators and manufacturers of pharmaceutical grade CBD products. Isodiol will provide its experience in research, development and manufacturing and offer all of its current products to Laguna on an exclusive basis for the Canadian market.
Laguna and Isodiol have entered into an exclusive license and distribution agreement for Canada for the purpose of pursuing mutually beneficial business opportunities in the Cannabidiol (CBD) Industry. Under the terms of the agreement Laguna agrees to issue 3,750,000 common shares (the “Consideration Shares”) subject to 6 month escrow. In Q4 2016, Isodiol recorded unaudited sales of $3,149,738 USD in CBD related sales in North America.
Ray Grimm Jr., President & CEO of Laguna Blends, said “Securing the highest quality CBD products for Canada is a pivotal step in our North American growth strategy. Isodiol is the dominant leader in the formulation and manufacturing of CBD products in the US and we are proud to align with the best of the best in the industry. I am confident Laguna will meet or exceed our projected sales goals now that we can offer all of Isodiol’s products. Ray Grimm went on to say. “Laguna is currently in negotiations with a third party in Canada that has extensive distribution channels for CBD and hemp products.”
ISO International COO, Troy Nihart stated, “We are looking forward to expanding in to the Canadian market with Laguna Blends. The market place there is quickly shifting and with the anticipation of the legal landscape in Canada changing, our goal is to work with Laguna and our proprietary extraction methods to be the leading supplier of pharmaceutical grade CBD in Canada.”
In connection with the closing of the Isodiol transaction, Kannafund Holdings LLC will be issued five hundred thousand common shares in consideration for over three months of consulting services in relation to this particular agreement.
About Laguna Blends Inc.
Laguna Blends is a market leader in the distribution of Hemp and CBD products. Lagunas growth strategy includes acquiring and incubating companies who formulate and or manufacture Hemp products. Laguna Blends markets Hemp products utilizing its B to B Network along with driving traffic to its Laguna Blends online marketplace.
It’s Lagunas intent to provide the highest quality hemp product experience for the end user, utilizing a proprietary nanotechnology in many of its consumable and topical skin care products. Laguna is currently seeking joint ventures and acquisitions to expand its portfolio and will aggressively begin international expansion into Asia and Europe in 2017.
About Iso International, LLC. (Isodiol)
Isodiol is a leading harvester, formulator and manufacturer of CBD related products.
Isodiol and it’s team of collaborators are a group of companies that together, grow & harvest hemp on an industrial scale, and then process it to extract the cannabidiol (CBD) to the highest available purity for worldwide distribution.
By utilizing one of the world’s largest hemp farms, Isodiol and its partners are the choice for industrial volumes of high grade CBD. Pharmaceutical, nutraceutical and cosmetic companies worldwide have gained market share due to our products.
Click here to connect with Laguna Blends (CSE:LAG; OTCMKTS:LAGBF; FRA:LB6A to receive an Investor Presentation.

The Conversation (0)
×